Amit K Dash, PhD
@amit-dash.bsky.social
Leveraging a strong foundation in Biochemistry, Molecular & Cellular biology, I am committed to bridging gap between basic and translational science, with a mission to improve patient outcomes by translating scientific discoveries into actionable therapies
Reposted by Amit K Dash, PhD
LBCA is happy to see that ILC and the need for targeted research is finally getting national attention thanks to this excellent report from the American Cancer Society, we are proud that LBCA's advocacy helped make it happen! pressroom.cancer.org/lobular-brea... #lobularbreastcancer #ilcawareness
Special ACS Report: Lesser-Known Lobular Breast Cancer on the Rise in U.S. Women
ATLANTA, October 7, 2025 — Today, the American Cancer Society released Lobular Breast Cancer Statistics, 2025, a report on occurrence and outcomes in the United States for this subtype of breast...
pressroom.cancer.org
October 8, 2025 at 12:42 AM
LBCA is happy to see that ILC and the need for targeted research is finally getting national attention thanks to this excellent report from the American Cancer Society, we are proud that LBCA's advocacy helped make it happen! pressroom.cancer.org/lobular-brea... #lobularbreastcancer #ilcawareness
Reposted by Amit K Dash, PhD
Today, we celebrate an important milestone - the 125th anniversary of the founding of the institution in Dallas. This set the course for our move to Houston and rise to prominence in education, research and patient care. https://bit.ly/48gfpG6 #BCMHouston
125 Years of Baylor College of Medicine
YouTube video by Baylor College of Medicine
www.youtube.com
September 15, 2025 at 5:07 PM
Today, we celebrate an important milestone - the 125th anniversary of the founding of the institution in Dallas. This set the course for our move to Houston and rise to prominence in education, research and patient care. https://bit.ly/48gfpG6 #BCMHouston
Reposted by Amit K Dash, PhD
A new study from researchers at Baylor College of Medicine brings hope for a more personalized approach to treat estrogen receptor-positive breast cancer. #breastcancer
One step closer to improving ER+ breast cancer patients' response to therapy
A new study from researchers at Baylor College of Medicine brings hope for a more personalized approach to treat estrogen receptor-positive (ER+) breast...
bit.ly
August 28, 2025 at 2:45 PM
A new study from researchers at Baylor College of Medicine brings hope for a more personalized approach to treat estrogen receptor-positive breast cancer. #breastcancer
Reposted by Amit K Dash, PhD
Today we honor @danieljdrucker.bsky.social at #ENDO2025, for being our Fred Conrad Koch Lifetime Achievement Award recipient, our highest honor that recognizes lifetime achievements and exceptional contributions to the field of #endocrinology: bit.ly/4l7fbEW
@endocrinenews.bsky.social
@endocrinenews.bsky.social
Meet the 2025 Laureate Award Winners - Endocrine News
For more than 80 years, the Endocrine Society has recognized the achievements of endocrinologists worldwide. The Laureate Awards recognize endocrinologists for seminal research, meritorious service, l...
bit.ly
July 12, 2025 at 3:58 PM
Today we honor @danieljdrucker.bsky.social at #ENDO2025, for being our Fred Conrad Koch Lifetime Achievement Award recipient, our highest honor that recognizes lifetime achievements and exceptional contributions to the field of #endocrinology: bit.ly/4l7fbEW
@endocrinenews.bsky.social
@endocrinenews.bsky.social
The FDA has granted De Novo authorization for CLAIRITY BREAST, a new first-in-class platform that predicts a woman’s future 5-year #breastcancer risk from routine screening mammography images using an artificial intelligence (AI) model
www.docwirenews.com/post/fda-aut...
www.docwirenews.com/post/fda-aut...
FDA Authorizes First AI Platform for Breast Cancer Risk Prediction | Docwire News
FDA authorizes CLAIRITY BREAST, the first AI tool to predict 5-year breast cancer risk from screening mammograms.
www.docwirenews.com
July 7, 2025 at 11:45 PM
The FDA has granted De Novo authorization for CLAIRITY BREAST, a new first-in-class platform that predicts a woman’s future 5-year #breastcancer risk from routine screening mammography images using an artificial intelligence (AI) model
www.docwirenews.com/post/fda-aut...
www.docwirenews.com/post/fda-aut...
The multilayered actions of #enhancers and associating regulatory DNAs, such as facilitators and Range Extenders, dynamically modulate the clustering of transcription machineries to flexibly control the dynamics of #geneexpression during development
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Multilayered Mechanisms for Long-range Regulatory Interactions in Eukaryotic Transcription
Transcription is a fundamental biological reaction that underlies essentially all developmental and physiological processes across species. While subs…
www.sciencedirect.com
July 6, 2025 at 6:01 PM
The multilayered actions of #enhancers and associating regulatory DNAs, such as facilitators and Range Extenders, dynamically modulate the clustering of transcription machineries to flexibly control the dynamics of #geneexpression during development
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
A recent thought-provoking study reported that chemotherapeutic drugs, such as doxorubicin and cisplatin, enhance the proliferation and lung metastasis of dormant #breastcancer cells by facilitating the formation of neutrophil extracellular traps (NETs).
pubmed.ncbi.nlm.nih.gov/40614736/
pubmed.ncbi.nlm.nih.gov/40614736/
Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps - PubMed
Disseminated tumor cells (DTCs) can remain in a non-proliferative, dormant state for years in distant organs, but the exogenous causes triggering their reactivation and metastatic colonization are unc...
pubmed.ncbi.nlm.nih.gov
July 6, 2025 at 5:40 AM
A recent thought-provoking study reported that chemotherapeutic drugs, such as doxorubicin and cisplatin, enhance the proliferation and lung metastasis of dormant #breastcancer cells by facilitating the formation of neutrophil extracellular traps (NETs).
pubmed.ncbi.nlm.nih.gov/40614736/
pubmed.ncbi.nlm.nih.gov/40614736/
A nice informative work from Drs. Wilbert Zwart and Andries M. Bergman's group identified a distinct subset of H3K27ac-differentially marked regions associated with treatment responsiveness in #mCRPC through epigenetic profiling of #enhancer/promoter activities.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer
Androgen receptor (AR) signaling inhibitors, including enzalutamide, are treatment options for patients with metastatic castration-resistant prostate …
www.sciencedirect.com
July 6, 2025 at 5:23 AM
A nice informative work from Drs. Wilbert Zwart and Andries M. Bergman's group identified a distinct subset of H3K27ac-differentially marked regions associated with treatment responsiveness in #mCRPC through epigenetic profiling of #enhancer/promoter activities.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...